Date: November 02, 2026

To,
Manager,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 533315

Dear Sir/Madam,

Sub: Investor Presentation

With reference to the subject, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2026.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For Innovassynth Technologies (India) Limited
(Formerly known as Innovassynth Investments Limited)

SAMEER SALIM PAKHALI
Digitally signed by SAMEER SALIM PAKHALI
Date: 2026.11.02 21:29:30 +05'30'

Sameer Pakhali
Company Secretary & Compliance Officer
ACS 55746



INNOVASSYNTH

Investor Presentation Q2FY27

2-November-2026

Chemistry of possibilities

Disclaimer

*"This presentation has been prepared by Innovassynth Technologies India Limited ("**Company**") (formerly known as Innovassynth Investments Limited).*

The presentation aims to cover key financial and business highlights. This presentation and some statements herein may be forward-looking statements and may not be based on historical information or facts and may be expressed in good faith and in the Company's management's opinion reasonable, including those relating to the Company's general business plans and strategy, its growth prospects and its competitive and regulatory environment. These statements are inherently subject to a variety of risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected based on risks relating to the execution, global supply chain, technological developments, geopolitical developments, etc.. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. This presentation does not aim to offer, and should not be viewed as providing, a complete or comprehensive assessment of the Company's business, financial performance, operating results, market position, or prospects. Furthermore, this presentation is not an offer, solicitation, or invitation to buy or subscribe for any securities of the Company."



Executive Summary and Financials

Executive Summary

Performance Update and Outlook

- EBITDA was impacted primarily by the spillover of certain sales scheduled for Q2 into the subsequent quarter and, to some extent, by higher costs of certain raw materials due to geopolitical developments in West Asia.
- Given the inherent nature of the CDMO business, revenues can be uneven across quarters depending on customer schedules, project milestones and commercialisation timelines. Accordingly, business performance is best assessed over a longer period rather than on a quarter-to-quarter basis.
- During the quarter, business performance remained resilient, with continued progress across key customer programmes despite a challenging operating environment.
- The order book stood at Rs. 137 crore as of 30th September 2026, providing healthy revenue visibility for the coming quarters.
- We continue to expand customer engagement across existing and new applications, creating a broader base of opportunities for future business conversion.
- Several customer molecules are progressing through different stages of development and commercialisation, with some programmes moving closer to commercial production. This progress has the potential to translate into additional volumes and contribute to future revenue growth.
- Based on the current business pipeline, order book and progress across customer programmes, we believe H2 performance is likely to be better than H1.

With continued progress across customer programs, increasing penetration across end-use applications and a focus on execution excellence, we remain confident of delivering improved business performance..


Executive Summary


Execution Highlights & Growth Drivers


- Life Sciences capacity expansion largely remains on track and is expected to enhance our ability to support future customer requirements and growth opportunities.
- We are undertaking debottlenecking initiatives across manufacturing facilities, including the installation of downstream equipment, to enhance throughput and increase effective production capacity.
- Certain manufacturing facilities underwent planned shutdowns of approximately 10 days during the quarter to facilitate debottlenecking and capacity enhancement activities.
- We are pursuing backward integration by developing in-house capabilities for critical raw materials to reduce dependence on China-based sourcing, strengthen supply chain resilience and improve overall margin.
- Several yield improvement initiatives are underway to enhance process efficiencies, particularly as production volumes increase, enabling us to become more competitive in larger-volume customer programmes.
- We continue to work on adopting new technologies and process innovations to improve existing products, enhance manufacturing capabilities and strengthen our competitive positioning.
- We successfully completed two major customer audits during the quarter, one each in Life Sciences and Specialty Chemicals, with no major observations, reaffirming the strength of our quality systems and compliance framework.
- We were awarded the EcoVadis Gold Rating for the third consecutive year, reflecting our continued commitment to sustainability, responsible business practices and ESG excellence.


Strong execution across customer programs, operational improvements and sustainability initiatives continues to strengthen our capabilities and position us for sustained future growth


H1 FY27 Financial Performance – Comparative Analysis














Amount in INR Lakhs, except percentage and EPS

Strategic Growth & Business Development Highlights

Open Order Book

Amount in INR Crores

Life Sciences	Specialty Chemicals	CDMO	Grand Total
INR ~73	**INR ~10**	**INR ~55**	**INR ~137**
Major orders from USA/EU based companies, with additional orders expected	Strong portfolio and custom product	Confirmed requirements shared by large global company	

Key Focus Areas



- Dedicated focus on Lifesciences and Spec Chem, custom and portfolio products with a defined cadence
- Effective order execution and scale-up to improve process efficiency and operational excellence
- Successful completion of several audits could result into improved customer confidence

Profit and Loss Statement

Particulars	Quarter Ended			6 Months Ended		Year Ended
	30-Sep-26	30-Jun-26	30 Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	4,755	5,599	1,728	10,353	2,955	10,235
Operating Expenses	(4,587)	(4,102)	(2,838)	(8,689)	(5.618)	(12,677)
EBIDTA	**168**	**1,497**	**(1,110)**	**1,664**	**(2,663)**	**(2,442)**
EBIDTA Margin (%)	4%	27%	(64%)	16%	(90%)	(24%)
Depreciation and Amortisation	(206)	(200)	(199)	(406)	(394)	(788)
Finance Cost	(113)	(200)	(176)	(313)	(311)	(723)
Other Income	315	19	30	334	38	61
Profit/(loss) before exceptional items and tax	**164**	**1,116**	**(1,454)**	**1,280**	**(3,329)**	**(3,892)**
Exceptional items	-	-	(21)	-	(22)	82
Profit/(loss) before tax	**164**	**1,116**	**(1,476)**	**1,280**	**(3,351)**	**(3,974)**
Tax expenses/(credit)	14	442	(48)	(456)	(219)	(1,095)
PAT	150	674	(1,428)	823	(3,132)	(2,879)
PAT Margin %	3%	12%	(83%)	8%	(106%)	(28%)
Other Comprehensive Income	-	-	-	-	-	30
Total Comprehensive Income	**150**	**674**	**(1,428)**	**823**	**(3,132)**	**(2,848)**
Diluted EPS (INR)	0.16	0.80	(1.89)	0.93	(4.15)	(3.82)

Amount in INR Lakhs, except percentage and EPS

Balance Sheet

Amount in INR Lakhs

Particulars	Q2 FY26	Q2 FY25
Assets		
Non-Current Assets		
Property, Plant and Equipment	12,395	12,161
Right of use assets	706	786
Capital work-in-progress	939	365
Other Intangible Assets	67	66
Financial Assets		
(i) Investment	162	162
(ii) Other Financial Assets	104	69
Deferred Tax Assets (net)	2,163	2,619
Other non-tax asset	273	158
	16,809	**16,386**
Current Assets		
Inventories	6,330	5,586
Trade Receivable	3,142	3,141
Cash and Cash Equivalent	150	34
Bank Balance – other than above	396	427
Other Current Asset	2,035	2,219
	12,053	**11,407**
Total Assets	**28,863**	**27,793**

Particulars	Q2 FY26	Q2 FY25
Equity and Liabilities		
Equity		
Equity, Shared Capital	9,286	7,545
Other equity	7,888	1,904
	17,174	**9,449**
Liabilities		
(i) Financial Liability - Borrowing	298	4,860
(ii) Financial Liability- Lease Liabilities	801	883
Provisions	239	208
	1,338	**5,951**
Current Liabilities		
(i) Financial Liabilities – Borrowing	2,717	5,368
(ii) Financial Liabilities - Lease Liabilities	160	152
(iii) Financial Liabilities - Trade Payables	3,588	3,962
(iv) Financial Liabilities – Other	411	377
Other current liabilities	2,130	965
Provisions	1,344	1,239
Current tax liabilities (net)	-	330
	10,351	**12,392**
Total Equity and Liabilities	**28,863**	**27,793**


Company Overview

Business Model

Innovassynth has 3 business units

Life Sciences & Nucleosides

Specialty Chemicals

Contract Research Development and Manufacturing

Exports Led Business : ~90% of revenue from global geographies with key focus on USA & EU

Our Life Sciences & Specialty Chemicals segments focus on developing niche products for customers, resulting in higher profit margins

State of the art manufacturing facility

Integrated Manufacturing Facility at Khopoli, near Mumbai, India

9 multipurpose manufacturing plants built to handle a wide range of chemical processes and production scales

CRDMO - Our comprehensive CRDMO services, from concept to commercialization

- Custom Research
- Contract Manufacturing
- Full Time Equivalent/Fee for Service
- Scale up to Commercial Products


- 50+ highly qualified scientists specializing in specialty intermediates, bulk chemicals for various applications
- Custom development and manufacturing as per customer requirements

Innovassynth – At a Glance

- Manufacturing plant in 60+ acres at Khopoli with 8 units
- 10+ Line with total reaction capacity of **250 KL+**
- **50L** to 10KL reactor sizes

- Equipment of various MOC : SSR, MSGLR, Glass AR
- ANF, ANFD, Centrifuge, Vacuum and Rotary Tray dryers
- Utilities to handle large scale and range

- Total Strength : 300+
- 50+ Scientists, 10+ PhDs and 50+ technical staff
- Skilled team of engineers and support staff



- 60 fume hoods catering to custom development for FTE/FFS
- Dedicated analytical lab

- Pharmaceuticals
- Diagnostics
- Electronics
- Flavours and Fragrances
- Semiconductors
- Polymers

- Oxidation, reduction, rearrangement reactions
- Friedel-crafts, homologation, Diels Alder, Diazotation, Suzuki
- Cryogenic reactions involving Grignard, n-BuLi, MeLi

Consistently Improving:Quality, Safety, Sustainability

ISO 27001:2022,
ISO 14001:2015,
ISO 45001:2018,
ISO 9001:2015

Ecovadis Gold Rating for the third consecutive year

SBTi and **Responsible Care** initiated in 2026

Preparedness and Training

- **Structured safety induction** for all workforce segments
- Recurring **EHS capability-building programs**
- **HAZOP embedded** into all scale-up workflows
- Periodic **emergency simulations** validating response readiness

Safety & Environmental Infrastructure


- **260 KL ETP** enabling compliant wastewater treatment
- **740 KL ZLD** system supporting sustainability goals
- **Integrated fire systems** (hydrants, DCP/CO_2/foam)
- Emergency sirens, eye wash stations & body showers

Health & Continuous Monitoring


- **24/7 Occupational Health Centre** with bed, creche & ambulance
- Annual & semi-annual **medical surveillance programs**
- Real-time **online monitoring** of boiler & process stacks
- Staff trained **in Emergency Procedures and First-Aid**

Capital Market Information

BSE Sensex Vs Innovassynth (ITIL) Share Price



Shareholding Pattern (as on 30-Sep-26)



Price Data as on 30-Sep-26	INR
Face Value	10
Market Price	154.3
52 Week H/L	154.3/142.65
Market Cap (Cr)	1432.84
Equity Shares Outstanding (# Cr)	9.28

INNOVASSYNTH

Thank You

